Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia

High doses of corticosteroids in combination with rituximab remain an alternative in the treatment in relapsed or refractory chronic lymphocytic leukaemia (CLL) in the current era of targeted therapies. This study retrospectively evaluates the efficacy of an RCD (rituximab, cyclophosphamide and dexa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical investigation 2021-04, Vol.51 (4), p.e13421-n/a
Hauptverfasser:	Šimkovič, Martin, Vodárek, Pavel, Motyčková, Monika, Écsiová, Dominika, Rozsívalová, Petra, Móciková, Heidi, Štěpánková, Pavla, Sýkorová, Alice, Hrochová, Kateřina, Vrbacký, Filip, Belada, David, Žák, Pavel, Smolej, Lukáš
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events chemoimmunotherapy chronic lymphocytic leukaemia Chronic lymphocytic leukemia Corticoids Corticosteroids Cyclophosphamide Dexamethasone Diabetes Diabetes mellitus Gene deletion Immunotherapy Karyotypes Leukemia Lymphadenopathy Monoclonal antibodies Mutation Neutropenia Patients Reduction Remission Rituximab Steroids Survival Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!